Navigation Links
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Date:9/3/2014

SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.  

The live presentation takes place on Wednesday, September 10 at 11:30am ET (8:30am PT).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.  

Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month.

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.  Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Reports Second Quarter 2014 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
3. Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
4. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
5. Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
6. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
8. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
9. Neurocrine Announces Phase IIb Results Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
10. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
11. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 27 Avril 2016   ... de +5% sur le trimestre, soutenu par une ... Croissance de +16% des ventes aux ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), ... annonce aujourd,hui son chiffre d,affaires pour le premier ...
(Date:4/27/2016)... , April 27, 2016 Transparency ... "Skincare Devices Market - Global Industry Analysis, Size, Share, ... the report, the global skincare devices market was valued ... to expand at a CAGR of 10.1% from 2015 ... Browse the full Skincare Devices Market (Treatment Device ...
(Date:4/27/2016)... Kan. , April 27, 2016  Bayer ... , a senior from the University of Florida ... of the Bayer Excellence in Communication Award (BECA). ... schools, which were awarded a total of $70,000 ... the last four years, Bayer has provided a ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... May 01, 2016 , ... Serenity Recovery, a ... rehabilitation, has produced a new video that focuses on one of the more popular ... sessions and clips from interviews with a participating patients and the Yoga class instructor, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... RANKED Health , a program to critically evaluate and rank health-focused applications and ... program is to provide independent, unbiased and accurate information to help accelerate patient ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) ... a minimally invasive procedure performed, when indicated, to correct the partial displacement ...
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent Marketing , ... Springboard, an automotive invention that improves the storage features of a pick up ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over the ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... Two Ten Footwear Foundation, the national charitable foundation serving the footwear industry, has ... 8,000 volunteers representing more than 130 companies across 23 states during the months ...
Breaking Medicine News(10 mins):